TYRAMINE

/static/temp/default.svg

Search structure


Synonyms	2-p-hydroxyphenylethylamine FEMA NO. 4215 NSC-249188 Ractopamine hydrochloride suspension impurity, tyramine- Systogene Tocosine Tyramine Tyrosamine Uteramine
Status
Molecule Category	UNKNOWN
UNII	X8ZC7V0OX3
EPA CompTox	DTXSID2043874


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DZGWFCGJZKJUFP-UHFFFAOYSA-N
Smiles	NCCc1ccc(O)cc1
InChI	InChI=1S/C8H11NO/c9-6-5-7-1-3-8(10)4-2-7/h1-4,10H,5-6,9H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C8H11NO
Molecular Weight	137.18
AlogP	0.89
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	2.0
Polar Surface Area	46.25
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	10.0

Assay Description	Organism	Bioactivity	Reference
Displacement of specifically bound [3H]naloxone from guinea pig ileum, in the presence of 100 mM NaCl	Cavia porcellus	0.001
Displacement of specifically bound [3H]naloxone from rat brain homogenate, in the absence of NaCl	Rattus norvegicus	0.001
Inhibitory activity against tyrosinase at 100uM	Homo sapiens	23.0 %
Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay	Homo sapiens	731.0 nM
PubChem BioAssay. Fluorescence-based cell-based high throughput dose response assay to identify agonists of the human trace amine associated receptor 1 (TAAR1). (Class of assay: confirmatory)	None	177.71 nM
PubChem BioAssay. Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput dose response assay to identify hTAAR1 agonist that also desensitize TAAR1 receptor response. (Class of assay: confirmatory)	None	881.84 nM
Antiprotozoal activity against clinical isolates of Giardia lamblia IMSS:8901:1	Giardia intestinalis	68.9 ug.mL-1
Antiprotozoal activity against clinical isolates of Entamoeba histolytica HM-1:IMSS	Entamoeba histolytica HM-1:IMSS	54.2 ug.mL-1
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	59.9 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	85.38 %
Agonist activity at rat N-terminal FLAG-tagged TAAR1 expressed in HEK293 cells assessed as [3H]cAMP accumulation measured after 1 hr	Rattus norvegicus	69.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	7.67 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.15 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.15 %
Agonist activity at recombinant human TAAR1 expressed in CHO-K1 cells assessed as increase in intracellular cAMP incubated for 30 mins by HTRF analysis	Homo sapiens	76.0 nM

Cross References

Resources	Reference
ChEBI	15760
ChEMBL	CHEMBL11608
DrugBank	DB08841
DrugCentral	2784
FDA SRS	X8ZC7V0OX3
Human Metabolome Database	HMDB0000306
Guide to Pharmacology	2150
KEGG	C00483
PDB	AEF
PubChem	5610
SureChEMBL	SCHEMBL4111
ZINC	ZINC000000002233

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).